Treatment of Early-Stage Favorable Classical Hodgkin Lymphoma in Adults with ESR Below 50 mm/hr and No Bulky Disease
This protocol covers adults aged 18–60 diagnosed with classical Hodgkin lymphoma at early stage (stage I–II) who meet all favorable-risk criteria. This specific clinical profile distinguishes a well-defined group for whom treatment approach and intensity are guided by the favorable designation.
Favorable-Risk Criteria — All Must Be Present
- No bulky mediastinal disease or mass greater than 10 cm
- No B symptoms (fever, night sweats, or weight loss)
- ESR below 50 mm/hr
- 3 or fewer nodal sites of disease
Patients with one or more of these risk factors present are classified as unfavorable and are managed along a different treatment path. Meeting all four criteria defines the favorable group addressed by this protocol.
Treatment Approach
Treatment in this setting involves chemotherapy — given alone or as part of a combined approach incorporating low-dose radiation to involved sites — with the specific regimen and extent of radiation guided by the patient's response during therapy. The complete regimen options and decision algorithm are available in the full protocol.
Response Goals
Response is assessed by PET-CT at interim (after two cycles of therapy) and at the end of treatment. The target is a negative PET result — a Deauville score of 1, 2, or 3 — indicating no remaining areas of concern and confirming complete disease remission.
References
- The NCCN Clinical Practice Guidelines look at the factors below to determine favorable (no risk factors) or unfavorable (one or more risk factors) for early-stage I-II HL: Bulky mediastinal disease or bulky disease greater than 10 cm, B symptoms (fever, night sweats, weight loss), Erythrocyte sedimentation rate (ESR) greater than 50 mm/hr, More than 3 nodal sites of disease.
- Having none of the risk factors listed below is considered favorable, whereas having one or more of the risk factors is considered unfavorable.
- The current treatment approach is to administer chemotherapy alone (without radiation therapy), or a combined modality therapy (combination chemotherapy followed by radiation therapy to areas of the body where lymphoma was found).
- For many years, ABVD has been the most commonly used chemotherapy regimen in adults for early-stage favorable HL.
- Current clinical practice guidelines for treatment of early-stage favorable HL suggest that at least 90 percent of patients can be cured with as few as two courses of ABVD followed by low-dose radiation therapy.
- Radiation can be used at the end of a chemotherapy regimen depending on how well the patient responded to the chemotherapy.
- A PET scan is typically performed after two cycles of therapy (interim PET) and at the end of therapy.
- A score of 1, 2 or 3 is considered negative, meaning there are no areas of concern.
View source ↗